Tech Company M&A Transactions
Myonexus Therapeutics Acquisition
Myonexus Therapeutics was bought by Sarepta Therapeutics. The transaction was announced on 2/27/2019. The companies indicated that total deal value was $165 million.
Transaction Overview
Company Name
Acquired By
Announced On
2/27/2019
Transaction Type
M&A
Amount
$165,000,000
M&A Terms
In May 2018, Sarepta and Myonexus entered into an exclusive partnership to develop Myonexus' five LGMD gene therapy candidates, which target the most severe and common forms of the disease. Financial terms of the transaction were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
8000 Walton Pkwy. 255
New Albany, OH 43054
USA
New Albany, OH 43054
USA
Phone
Website
Email Address
Overview
Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children's Hospital, a leader in muscular dystrophy gene therapy discovery and translational research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Triplett
Chief Financial Officer
Peter Kleinhenz
Chief Operating Officer
Bruce Halpryn
Chief Scientific Officer
Louise Rodino-Klapac
Browse more venture capital transactions:
Prev: 2/27/2019: Oyster Point Pharmaceuticals venture capital transaction
Next: 2/27/2019: Medstack venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs